Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference

Neurology

Volumn 46, Issue 1, 1996, Pages 12-18

  Lublin, F D ^a   Whitaker, J N ^b   Eidelman, B H ^c   Miller, A E ^d   Arnason, B G W ^e   Burks, J S ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Rocky Mountain MS Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; BETA1 INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MUSCLE RELAXANT AGENT; PREDNISONE;

BREAST FEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; HUMAN; INFLUENZA; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; SPASTICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SUICIDAL BEHAVIOR;

EID: 0029948580     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.12     Document Type: Review

References (18)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
3. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994; 44:1537-1540.
4. Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36(suppl):S86-S90.
5. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
6. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
7. Betaseron (Interferon beta-1b) Package Insert. Richmond, CA: Berlex Laboratories, July 1993.
8. Birk K, Ford C, Smeltzer S, Ryan D, Miller R, Rudick RA. The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990;47:738-742.
9. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769.
10. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
11. Wolinsky JS. Copolymer 1 - a most reasonable alternative therapy for early relapsing multiple sclerosis with mild disability. Neurology 1995;45:1245-1247.
12. Camenga DL, Johnson KP, Alter M, et al. Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986;43:1239-1246.
13. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67.
14. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40:1764-1769.
15. Davie CA, Hawkins CP, Barker GI, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
16. Gonzalez CF, Vinitski S, Seshagiri S, Lublin FD, Knobler RL. Volumetric regional analysis of MS lesions of the brain using 3D segmentation [abstract]. Neurology 1994;44(suppl 2): A339-A340.
17. Whitaker JN, Bradley EL, Burgard S, et al. Urinary myelin basic protein-like material as a correlate of the progressive phase of multiple sclerosis [abstract]. Ann Neurol 1994;36: 259-260.
18. Jacobs L, Cookfair D, Rudick R, et al. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis [abstract]. Ann Neurol 1994;36: 259.